Interestingly, in vivo AMPK activation alleviated the traumatic role of hyperglycemia in APAP-induced liver injury, as evidenced by lower serum ALT and AST levels (Fig. 7a, b), decreased liver architecture damage (Fig. 7c), and decreased hepatocellular apoptosis (Fig. 7d–f) compared to APAP treatment alone. This evidence concerns the gene GPT and Hyperglycemia.